相关实验视频

Updated: Jun 17, 2025

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

[^99mTc]Tc-PSMA SPECT/CT对前列腺癌的诊断疗效:一个元分析

Qi Wang^1,2, Svea Ketteler¹, Shamim Bagheri¹

¹Department of Nuclear Medicine, University Hospital Marburg, Philipps University Marburg, Baldinger-Strasse, 35043, Marburg, Germany.

|August 8, 2024

概括

标有Technetium-99m的前列腺特异性膜抗原 (PSMA) SPECT/CT显示了诊断前列腺癌的高准确性. 这种成像技术在-68 PSMA PET/CT无法使用的情况下提供了有价值的替代方案.

科学领域:

核医学是一种核医学.
放射性药物放射性药物放射性药物
在瘤学瘤学.

背景情况:

准确的前列腺癌 (PCa) 诊断对于治疗计划至关重要.
标有PSMA PET/CT标签的-68是有效的,但其可用性有限.
[^99mTc]Tc-PSMA SPECT/CT是一种有希望的替代成像方式.

研究的目的:

系统地审查和对Tc-PSMA SPECT/CT用于前列腺癌检测的诊断性能进行元分析.
为了评估它的准确性与既定方法相比.
评估其在资源有限的环境中的实用性.

主要方法:

在多个数据库中进行了全面的文献搜索,截至2024年7月.
提取和聚合了灵敏度,特异性和其他诊断准确度指标.
使用QUADAS-2工具评估研究质量,使用STATA 18和MetaDisc 1.4.进行统计分析.

主要成果:

七项研究被纳入了元分析,没有观察到出版偏差.
聚合灵敏度为0.89 (95% CI,0.84-0.93) 和聚合特异性为0.92 (95% CI,0.67-0.99). 聚合灵敏度是0.89 (95% CI,0.84-0.93) 和聚合特异性是0.92 (95% CI,0.67-0.99). 聚合灵敏度是0.89 (95% CI,0.84-0.93) 和聚合特异性是0.92 (95% CI,0.67-0.99).
曲线下的面积 (AUC) 为0.93 (95% CI,0.90-0.95),表明诊断的准确性很高.

结论:

[Tc]Tc-PSMA SPECT/CT显示前列腺癌的诊断性能良好.
它作为一种有价值的补充工具,特别是在[⁶⁸Ga]Ga-PSMA PET/CT有限的地区.
建议在更大的队列中进一步验证,以巩固其在PCa管理中的作用.

关键词:

进行元分析分析.在PSMA上,PSMA可以在PSMA上进行交易.前列腺癌是什么意思前列腺癌是什么意思在SPECT/CT测试中,这里是Technetium的技术.

更多相关视频

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...